Modulating Movement Intention Via Cortical Stimulation

Last updated: January 28, 2025
Sponsor: NYU Langone Health
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epilepsy

Tardive Dyskinesia

Dystonias

Treatment

Sham TMS3 stimulation

rTMS of left or right angular gyrus (AG) or frontal cortex (FC)

Anodal tDCS of left or right AG or FC

Clinical Study ID

NCT03233399
16-01859
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

(Healthy Controls)

  • Fluent in English

(Patients with PMD or PNES):

  • Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movementdisorders.

  • Per the treating neurologist, subject is unlikely to require treatment and/or dosagechanges for 3-6 months following screening

Exclusion

Exclusion Criteria:

  • Any history of a significant neurological disorder, which may interfere with theinterpretation of study data, as determined by the PI

  • Chronic or progressive medical condition

  • Any history of traumatic brain injury or significant head trauma

  • Currently meets criteria for substance abuse or dependence

  • History of any psychotic disorder or other psychiatric condition which may interferewith data interpretation

  • Pregnancy

  • Metal or devices in the head, including neurostimulators or metal foreign bodies

  • Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.

  • Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).

  • Taking tricyclic antidepressant or antiepileptic medications or CNS active drugsunder "strong potential hazard" list in Rossi et al., 2009

  • Current diagnosis of any inflammatory or autoimmune disorder within last 6 months

PMD and PNES Patients

  • Any history of traumatic brain injury or significant head trauma

  • Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonicseizures;

  • Neurological disorder other than PMD and PNES including stroke, fainting spells orsyncope of unknown cause(s);

  • Major or unstable medical illness, especially any current diagnosis of inflammatoryor autoimmune disorders within last 6 months

  • Metal or devices in the head, including neurostimulators or metal foreign bodies

  • Taking tricyclic antidepressant medications or CNS active drugs under "strongpotential hazard" list in Rossi et al., 2009;

  • Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;

  • Recurrent visual hallucinations, within the past 6 months;

  • History of significant uncontrollable movements of the head;

  • Any clinically significant abnormality on vital signs

Study Design

Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Sham TMS3 stimulation
Phase:
Study Start date:
July 20, 2017
Estimated Completion Date:
May 31, 2027

Study Description

This study will:

  • Explore effects of TMS and tDCS on movement intention.

  • Discern the neural activity underlying modulation of movement intention with neuroimaging recording.

  • Identify brain stimulation's effect in patients with psychogenic tremor and non-epileptic seizures.

  • Technical development of new experimental paradigms and data analysis methods.

  • Data collection for hypotheses development.

Connect with a study center

  • New York University School of Medicine

    New York, New York 10016
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.